Breaking News
December 12, 2017 - CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients
December 12, 2017 - Live-cell microscopy reveals internal forces that direct cell migration
December 12, 2017 - GSK Submits US Regulatory Application for Single-Dose Tafenoquine for Plasmodium vivax Malaria
December 12, 2017 - High Blood Urea Nitrogen Levels Tied to T2D Risk
December 12, 2017 - Blood Smear: MedlinePlus Lab Test Information
December 12, 2017 - Atopic eczema—one size does not fit all
December 12, 2017 - Biological Applications of AFM
December 12, 2017 - Study provides new insights into mechanism of tumor survival in glioblastoma
December 12, 2017 - FDA Approves Admelog (insulin lispro) Short-Acting “Follow-On” Insulin Product to Treat Diabetes
December 12, 2017 - Chromosomes Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - Discovery puts the brakes on HIV’s ability to infect
December 12, 2017 - Researchers uncover novel strategy to program immune system for fighting cancer
December 12, 2017 - Study finds under-age marriage for women as marker of multiple vulnerabilities
December 12, 2017 - Scientists discover specific mechanism of Zika virus-associated microcephaly
December 12, 2017 - Creating Your Family Health Tree
December 12, 2017 - Biological Pathways Fact Sheet – National Human Genome Research Institute (NHGRI)
December 12, 2017 - LSUHealthNO breakthrough may pave way for advances in obesity-related diseases
December 12, 2017 - Few people with HIV get prompt care after incarceration
December 11, 2017 - Air pollution exposure before or after conception linked to increased risk of birth defects in children
December 11, 2017 - Abu Dhabi focuses on reducing childhood obesity
December 11, 2017 - Employees with influenza have more lost work time
December 11, 2017 - type 2 diabetes – Genetics Home Reference
December 11, 2017 - Insufficient evidence to guide recommendations on vitamin D in pregnancy
December 11, 2017 - St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease
December 11, 2017 - Soy foods, cruciferous vegetables may reduce breast cancer treatment’s side effects
December 11, 2017 - Nearly 3 in 10 elite footballers at top clubs have undetected lung and airway problems, study finds
December 11, 2017 - Why some workers can’t call it quits
December 11, 2017 - Healthier Diet, Less Salt: The Recipe to Beat High Blood Pressure: MedlinePlus Health News
December 11, 2017 - Research leads to call for lung health screening at top football clubs
December 11, 2017 - Drug improves disease-free, overall survival after hematopoietic stem cell transplants
December 11, 2017 - Researchers generate 3D cell cultures to investigate mechanisms of drug resistance in breast cancer
December 11, 2017 - New, more easily administered therapies offer benefits for bleeding and clotting disorders
December 11, 2017 - Opioids after surgery left her addicted. Is that a medical error?
December 11, 2017 - Scientists develop software that predicts leukemia-specific immune targets
December 11, 2017 - Does Your Pet Have a Weight Problem? Here’s How to Tell: MedlinePlus Health News
December 11, 2017 - Genetic variant prompts cells to store fat, fueling obesity
December 11, 2017 - Canola oil linked to worsening of Alzheimer’s
December 11, 2017 - New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too
December 11, 2017 - Healthy Living May Ease Some MS Symptoms: MedlinePlus Health News
December 11, 2017 - Researchers develop a molecular taxonomy for hair disorders
December 11, 2017 - Study shows safety, efficacy of cystic fibrosis drug in children between 1 to 2 years of age
December 11, 2017 - Two immunotherapy approaches for multiple myeloma show hope
December 11, 2017 - The Valley Hospital uses novel mobile app to enhance pre-hospital emergency care
December 11, 2017 - ‘I Entered Medical School Through a Hunger Strike’: What We Heard This Week
December 11, 2017 - Research team unlocks secrets of Ebola
December 11, 2017 - Generic versions of Viagra coming this week
December 11, 2017 - New genetic model identified for predicting outcomes in patients with primary myelofibrosis
December 11, 2017 - Research shows that e-cigarettes serve as gateway to traditional smoking
December 11, 2017 - A risk factor for drug-induced skin disease identified
December 11, 2017 - MIT researchers discover new way to make bacteria vulnerable to existing antibiotics
December 11, 2017 - Dengue vaccine issues in the Philippines
December 11, 2017 - Office Workers Don’t Like Being Chained to Their Desks: MedlinePlus Health News
December 11, 2017 - Study reveals how a very low calorie diet can reverse type 2 diabetes
December 11, 2017 - Study highlights potential for reducing greenhouse gas emissions in health care settings
December 11, 2017 - University of Adelaide receives $23.2 million for preterm birth research
December 11, 2017 - Tough Flu Season Ahead: Vaccine May Only Be 10% Effective
December 11, 2017 - Getting Self-Driving Cars on the Road Soon Might Save Lives: MedlinePlus Health News
December 11, 2017 - Enterovirus vaccine prevents virus-induced diabetes in a T1D experimental model
December 11, 2017 - Solar retinopathy or sun damage to the eyes – a case report
December 11, 2017 - Cancer risk with birth control pills emerges again in latest study
December 10, 2017 - Deer Hunters: Put Safety First: MedlinePlus Health News
December 10, 2017 - High blood pressure is redefined as 130, not 140: US guidelines (Update)
December 10, 2017 - Unusual neuroinflammation may underlie cognitive problems in cART-treated HIV patients
December 10, 2017 - Racial differences in parents’ reports of child’s autism symptoms may contribute to delayed diagnosis
December 10, 2017 - Taurine could boost effectiveness of existing multiple sclerosis therapies
December 10, 2017 - The man with a young woman’s heart
December 10, 2017 - Patient bedside remains important component of medical education for students
December 10, 2017 - Nutrition labeling has little impact on sodium consumption
December 10, 2017 - ‘Obesity paradox’ not present among people with new cases of cardiovascular disease
December 10, 2017 - SLU scientists provide promising approach in designing new drugs for DMD
December 10, 2017 - Can PD-1 Inhibitor Help Eradicate HIV?
December 10, 2017 - Checking Prices for Medical Procedures Online? Good Luck: MedlinePlus Health News
December 10, 2017 - Researchers find bacteria tied to esophageal cancer
December 10, 2017 - Boy’s Double Hand Transplant Changed His Brain
December 10, 2017 - Memo to Doctors: Spit Out the Bad News: MedlinePlus Health News
December 10, 2017 - Two years of extended anastrozole therapy proved as effective as five years in clinical trial
December 10, 2017 - Using digital devices before bed may contribute to sleep and nutrition problems in children
December 10, 2017 - Are You Sure That’s What the Doctor Said About Your Leukemia?: MedlinePlus Health News
December 10, 2017 - Low vitamin D levels at birth linked to higher autism risk
December 10, 2017 - Alcohol use in movies influences onset of drinking among 10- to 15-year-olds
FDA Approves Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep

FDA Approves Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep

image_pdfDownload PDFimage_print

FDA Approves Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep

Parsippany, NJ – November 29, 2017 – The U.S. Food and Drug Administration (FDA) has granted Ferring Pharmaceuticals Inc. approval to market Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution for cleansing of the colon in adults undergoing a colonoscopy. With availability planned in Q1 2018, Clenpiq will be the only FDA-approved prescription colonoscopy prep that comes “ready-to-drink”.

Colorectal cancer is the third most common cancer and second leading cause of cancer death in the United States.1 Colonoscopies can help reduce the incidence of colorectal cancer and deaths associated with this disease.2,3,4

“Successful bowel prep is critical for gastroenterologists to clearly see the inside of the colon during a colonoscopy. The sheer volume of a prescribed bowel prep solution can be a barrier for some patients to adequately complete their prep regimen, leading to suboptimal visualization of the colon,” said Dr. Edward Brettholz, Clinical Assistant Professor of Medicine, NYU School of Medicine. “Having a ready-to-drink, low volume colonoscopy prep in a pre-mixed oral solution is an excellent start to prepare patients for this important procedure to help detect and prevent colorectal cancer.”

“We are delighted to add Clenpiq to our gastroenterology portfolio,” said Paul Navarre, CEO, Ferring Holding Inc. “We expect that a ready-to-drink bowel preparation will aid physicians in their efforts to encourage colonoscopies among a patient population for whom various public health initiatives have called for increased screening.”

About Clenpiq

Clenpiq is a ready-to-drink cranberry-flavored, dual-acting, combination of sodium picosulfate, a stimulant laxative, and magnesium oxide and anhydrous citric acid, which forms magnesium citrate, an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults.5

Important Safety Information

  • Clenpiq is contraindicated in the following conditions: patients with severe renal impairment (creatnine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in Clenpiq.
  • Patients should be advised to hydrate adequately (before, during and after use of Clenpiq), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking Clenpiq. Patients with electrolyte abnormalities should have them corrected before treatment.
  • Use caution when prescribing Clenpiq for patients that have conditions or are using medications that may increase the risk for fluid and electrolyte abnormalities.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with Clenpiq may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of Clenpiq.
  • The safety of Clenpiq has been established from adequate well controlled trials of another formulation of sodium picosulfate, magnesium oxide and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.
  • Clenpiq can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting Clenpiq. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. For more information, call 1-888-FERRING (1- 888-337-7464); visit www.FerringUSA.com or www.clenpiq.com

Ferring acquired global rights (excluding Korea) to the stable liquid formulation used in Clenpiq from Pharmbio Korea co., Ltd.

References:

1 U.S. Center for Disease Control and Prevention. Colorectal Cancer Statistics. https://www.cdc.gov/cancer/colorectal/statistics/index.htm. Last updated: March 23, 2017.
2 American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Atlanta: American Cancer Society; 2017.
3 Brenner, et al. Potential for Colorectal Cancer Prevention of Sigmoidoscopy Versus Colonoscopy: Population- Based Case Control Study. Cancer Epidemiol Biomarkers Prev. 2007; 16:494-499.
4 Khai, et al. Effect of Screening Colonoscopy on Colorectal Cancer Incidence and Mortality. Clinical Gastroenterology and Hepatology. 2009; 7:770–775.
5 CLENPIQ™ [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.

Source: Ferring Pharmaceuticals Inc.

Posted: November 2017

Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) FDA Approval History

Tagged with:

About author

Related Articles